Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium -177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Non-small Cell Lung Cancer